Assessing a Clinically-meaningful Opioid Withdrawal Phenotype (NCT05027919)

🧪 Interventions in This Study

• Hydromorphone (DRUG)
• Naloxone + lofexidine pretreatment (DRUG)
• Naloxone + placebo pretreatment (DRUG)
• Lofexidine (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

• University of Maryland — Baltimore, Maryland

📞 Contact the Study Coordinator

Phone: (802) 922-1682

Email: kelly.dunn@som.umaryland.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Opioid Withdrawal

• Sensing Physiological Symptoms of Opioid Withdrawal and Cravings in Patients With Opioid Use Disorder — Center City, Minnesota
• ACTION: Trial of Adding Buprenorphine, CBT, and TMS to Improve Outcomes of Long-Term Opioid Therapy for Chronic Pain — Charleston, South Carolina
• Understanding the Effects of Transcutaneous Auricular Neurostimulation for Treatment of Chronic Pain — Galveston, Texas
• Sparrow Link Neuromodulation Device for Opioid Withdrawal Management in Hospitalized Adults With Opioid Use Disorder — Pittsburgh, Pennsylvania

Explore by condition: All Opioid Withdrawal clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.